title: Comment on Zhang et Al. Second-line agents for glycemic control for type 2 diabetes: are newer agents better? Diabetes Care 2014;37:1338-1345.
authors.affiliation: Eli Lilly and Company, Indianapolis, IN.
authors.forename: Jay
authors.initials: J
authors.lastname: Bae
authors.affiliation: Eli Lilly and Company, Indianapolis, IN curtis_bradley_h@lilly.com.
authors.forename: Bradley H
authors.initials: BH
authors.lastname: Curtis
authors.affiliation: Eli Lilly and Company, Indianapolis, IN.
authors.forename: David M
authors.initials: DM
authors.lastname: Kendall
authors.affiliation: Eli Lilly and Company, Indianapolis, IN.
authors.forename: Robert J
authors.initials: RJ
authors.lastname: Heine
mesh_terms: D003924:Diabetes Mellitus, Type 2 / Q000517:prevention & control*; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D008297:Male
chemical_list: D007004:Hypoglycemic Agents